IsoRay, Inc. (DE) (ISR): Price and Financial Metrics

IsoRay, Inc. (DE) (ISR): $0.38

0.00 (0.03%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

ISR Price/Volume Stats

Current price $0.38 52-week high $0.45
Prev. close $0.38 52-week low $0.19
Day low $0.36 Volume 145,000
Day high $0.39 Avg. volume 290,697
50-day MA $0.32 Dividend yield N/A
200-day MA $0.33 Market Cap 54.57M

ISR Stock Price Chart Interactive Chart >


IsoRay, Inc. (DE) (ISR) Company Bio


Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.


ISR Latest News Stream


Event/Time News Detail
Loading, please wait...

ISR Latest Social Stream


Loading social stream, please wait...

View Full ISR Social Stream

Latest ISR News From Around the Web

Below are the latest news stories about ISORAY INC that investors may wish to consider to help them evaluate ISR as an investment opportunity.

IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 16, 2023

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

Fiscal Calendar Year Changes from June to December Year EndRICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended Decem

Yahoo | February 16, 2023

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business a

Yahoo | February 7, 2023

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

RICHLAND, Wash. & CORALVILLE, Iowa, February 06, 2023--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor site

Yahoo | February 6, 2023

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

Stockholders Approve Proposal One Clearing Way for Consummation of MergerRICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation

Yahoo | January 30, 2023

Read More 'ISR' Stories Here

ISR Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -63.11%
5-year -1.30%
YTD N/A
2023 0.00%
2022 -36.28%
2021 -13.82%
2020 -27.93%
2019 108.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!